Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

OPT

Opthea Limited ADR

Jun 21 • 03:43PM ET

2.00

Dollar change -0.04
Percentage change -1.96	%

Healthcare • Biotechnology • Australia • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.17	Insider Own	-	Shs Outstand	150.76M	Perf Week	-20.00%
Market Cap	301.52M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-	Shs Float	82.85M	Perf Month	-44.60%
Income	-161.86M	PEG	-	EPS next Q	-	Inst Own	5.48%	Short Float	0.09%	Perf Quarter	-42.86%
Sales	0.12M	P/S	2512.67	EPS this Y	47.78%	Inst Trans	-	Short Ratio	2.90	Perf Half Y	-18.37%
Book/sh	-0.52	P/B	-	EPS next Y	41.01%	ROA	-101.00%	Short Interest	0.07M	Perf Year	-39.39%
Cash/sh	1.04	P/C	1.92	EPS next 5Y	-	ROE	-3388.40%	52W Range	1.60 - 4.40	Perf YTD	-32.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-37.62%	ROI	-120.88%	52W High	-54.55%	Beta	-
Dividend TTM	-	Quick Ratio	5.10	Sales past 5Y	13.73%	Gross Margin	-	52W Low	25.00%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	5.10	EPS Y/Y TTM	-192.97%	Oper. Margin	-141208.56%	RSI (14)	24.66	Volatility	15.30% 8.60%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-138173.67%	Recom	1.40	Target Price	9.88
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-5.23%	Payout	-	Rel Volume	0.23	Prev Close	2.04
Sales Surprise	143.20%	EPS Surprise	-36.67%	Sales Q/Q	17.75%	Earnings	Feb 28 AMC	Avg Volume	24.59K	Price	2.00
SMA20	-29.74%	SMA50	-39.02%	SMA200	-26.90%	Trades		Volume	5,594	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-22	Initiated	H.C. Wainwright	Buy	$14
Apr-26-22	Initiated	SVB Leerink	Outperform	$25
Nov-17-20	Initiated	Citigroup	Buy	$48
Nov-11-20	Initiated	Truist	Buy	$25
Nov-11-20	Initiated	SVB Leerink	Outperform	$33
Nov-11-20	Initiated	Oppenheimer	Outperform	$36

Jun-18-24 08:57PM	Opthea A$55.0m (US$36.9m ) Retail Entitlement Offer Opens (GlobeNewswire) +9.09%
Jun-13-24 07:58PM	Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) (GlobeNewswire)
Jun-11-24 09:13PM	Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million ) (GlobeNewswire)
Jun-03-24 07:30AM	Opthea To Present at Clinical Trials at the Summit Meeting (GlobeNewswire) -6.34%
May-28-24 07:30AM	Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD (GlobeNewswire)
07:30AM	Loading…
May-01-24 07:30AM	Opthea Announces Upcoming Presentations at the Retina World Congress 2024 (GlobeNewswire)
Apr-25-24 09:00AM	Opthea to Present at the OIS Retina Innovation Summit at ARVO (GlobeNewswire) +5.83%
Apr-08-24 06:42PM	Opthea Appoints John Han, PharmD, as VP Medical Affairs (GlobeNewswire) -6.25% +8.00%
Apr-04-24 06:34PM	Opthea to Participate in the 23?? Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-24 05:39PM	Opthea Appoints Sujal Shah to the Board of Directors (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-19-24 06:00AM	Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024 (GlobeNewswire)
Mar-05-24 05:08PM	Opthea to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -7.49%
Feb-28-24 05:55PM	Opthea Reports Half-Year Financial Results and Business Updates (GlobeNewswire)
Feb-19-24 06:25PM	Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor (GlobeNewswire)
07:00AM	Loading…
Feb-14-24 07:00AM	Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept (GlobeNewswire)
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey) +11.79%
Feb-01-24 06:00AM	Opthea Strengthens Team with Key Clinical and Regulatory Hires (GlobeNewswire)
Dec-27-23 06:00AM	Opthea to Receive US$35M Commitment and Additional US$50M Funding (GlobeNewswire) +18.66%
Dec-19-23 06:00AM	Opthea Receives A$8.8 million R&D Tax Incentive (GlobeNewswire) -6.82%
Dec-01-23 05:30AM	Opthea to Present at the FLORetina 2023 Congress (GlobeNewswire) -5.06%
Nov-09-23 05:30AM	Opthea to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Oct-30-23 05:30AM	Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference (GlobeNewswire)
Oct-27-23 05:30AM	Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO (GlobeNewswire)
Oct-02-23 05:30AM	Opthea to Participate at the 2023 Euretina Congress (GlobeNewswire)
Sep-07-23 05:30AM	Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 05:30AM	Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹) (GlobeNewswire) -20.74%
Jul-26-23 06:00AM	Opthea Announces Sozinibercept as the Nonproprietary Drug Name for OPT-302 (GlobeNewswire)
Jul-24-23 06:00AM	Opthea to Present at the 2023 Ophthalmology Innovation Summit (GlobeNewswire)
Jul-13-23 06:00AM	Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting (GlobeNewswire) +6.03%
06:00AM	Loading…
Jul-10-23 06:00AM	Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor (GlobeNewswire)
Jun-08-23 06:00AM	Opthea Appoints Anshul Thakral as Non-Executive Director of the Board (GlobeNewswire)
May-25-23 08:00AM	Optiva and lifecell Named as a Nominee in TM Forum's 16th Annual Excellence Awards (PR Newswire)
06:00AM	Opthea to Present at the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-17-23 06:00AM	Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market (GlobeNewswire)
May-08-23 05:30AM	Opthea To Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-28-23 05:30AM	Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ (GlobeNewswire) +6.57%
Mar-07-23 06:00AM	Opthea Receives A$8.7 million R&D Tax Incentive (GlobeNewswire)
Mar-06-23 06:00AM	Opthea To Participate in Fireside Chat at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-13-23 06:00AM	Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology (GlobeNewswire)
Feb-06-23 06:00AM	Opthea To Present at SVB Leerink Global Biopharma Conference (GlobeNewswire)
Jan-30-23 06:00AM	Opthea To Present at Sequire Biotechnology Conference (GlobeNewswire) +6.91%
Dec-12-22 10:08AM	Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD (GlobeNewswire)
Dec-09-22 03:00PM	Opthea Limited's (ASX:OPT) top owners are individual investors with 44% stake, while 26% is held by hedge funds (Simply Wall St.)
Dec-06-22 06:00AM	Opthea to Present at the FLORetina 2022 Congress (GlobeNewswire) +5.31%
Nov-10-22 06:00AM	Opthea to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-22 06:00AM	Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer (GlobeNewswire)
Sep-18-22 07:15PM	Here's Why Opthea (ASX:OPT) Must Use Its Cash Wisely (Simply Wall St.)
Aug-30-22 06:00AM	Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-16-22 07:46AM	Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-14-22 09:02PM	Opthea Successfully Closes Well Supported US$90 Million Equity Financing (GlobeNewswire)
09:01PM	Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD (GlobeNewswire)
Jun-19-22 07:05PM	Could The Opthea Limited (ASX:OPT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
May-11-22 08:00AM	Opthea To Present at Upcoming Investor Conferences (GlobeNewswire) +6.61%
May-10-22 08:20AM	Opthea Presentation at The Retina World Congress 2022 (GlobeNewswire)
May-05-22 06:00AM	Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022 (GlobeNewswire) +8.21%
Apr-29-22 06:00AM	Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting (GlobeNewswire) +7.15%
Apr-22-22 08:15AM	Opthea strengthens its Board of Directors (GlobeNewswire)
Apr-10-22 08:12PM	Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation (Simply Wall St.)
Mar-21-22 04:00AM	Statement of Solidarity With the People of Ukraine From Optiva (PR Newswire) +5.61%
Mar-10-22 06:00AM	Opthea To Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-02-22 06:00AM	Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer (GlobeNewswire)
Feb-14-22 09:06AM	Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration (Benzinga) -8.05%
06:00AM	Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 (GlobeNewswire)
Feb-10-22 06:00AM	Opthea To Present at SVB Leerink Global Healthcare Conference (GlobeNewswire) +5.26%
Feb-09-22 06:00AM	Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference (GlobeNewswire)
Jan-24-22 06:00AM	Opthea Receives A$6.6 m R&D Tax Incentive (GlobeNewswire)
Jan-10-22 05:59PM	Is Opthea Limited (ASX:OPT) Popular Amongst Institutions? (Simply Wall St.)
Jan-04-22 06:18AM	Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Jan-03-22 06:00AM	Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD (GlobeNewswire)
Oct-26-21 06:00AM	Opthea Granted Chinese Patent Covering OPT-302 (GlobeNewswire)
Oct-19-21 06:00AM	Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD (GlobeNewswire)
Oct-12-21 05:41PM	Why We Think Opthea Limited's (ASX:OPT) CEO Compensation Is Not Excessive At All (Simply Wall St.)
Oct-04-21 07:00AM	Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 (GlobeNewswire)
Sep-07-21 08:20PM	We're Not Very Worried About Opthea's (ASX:OPT) Cash Burn Rate (Simply Wall St.)
Sep-02-21 07:00AM	Opthea To Present at September Investor Conferences (GlobeNewswire)
Aug-30-21 07:00AM	Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-10-21 07:00AM	Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-21 07:00AM	Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada (GlobeNewswire)
Jul-06-21 07:00AM	Optheas OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration (GlobeNewswire) +8.18%
Jun-16-21 04:06PM	Why Opthea Stock Skyrocketed Today (Motley Fool) +20.38% -12.08%
Jun-15-21 12:27PM	Is Opthea Limited (OPT) A Good Stock To Buy? (Insider Monkey) -7.15%
Jun-14-21 07:00AM	Opthea Appoints Company Secretary and Vice President of Finance (GlobeNewswire)
Jun-01-21 07:11AM	Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors (GlobeNewswire) +7.76%
May-31-21 04:27PM	Could The Opthea Limited (ASX:OPT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Apr-06-21 05:30AM	Opthea Company Secretary Resignation (GlobeNewswire) +5.27%
Mar-31-21 05:30AM	Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD (GlobeNewswire) +7.53%
Mar-15-21 05:30AM	Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD (GlobeNewswire) +6.82%
Mar-10-21 05:30AM	Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Mar-02-21 02:20PM	Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation (Simply Wall St.) +6.49%
Feb-24-21 05:30AM	Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD (GlobeNewswire)
Feb-17-21 05:30AM	Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Oct-20-20 09:38PM	Loss-Making Opthea Limited (ASX:OPT) Expected To Breakeven In The Medium-Term (Simply Wall St.)

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OPT

Opthea Limited ADR

Upgrade your FINVIZ experience